The drugmaker reports third-quarter earnings of $2 a share on revenue of $10.97 billion.
Bristol Myers Squibb posted third-quarter earnings and revenue that beat Wall Street estimates, but sales of drug Revlimid fell.
Last year, the company reported third-quarter earnings of $1.99 a share on revenue of $11.22 billion. Bristol Myers said that the decline in revenue was due to lower sales of cancer-fighting drug Revlimid.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Bristol Myers says it needs another year to hit target for new drugsDrugmaker Bristol Myers Squibb (BMY.N) on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as the ramp-up of new drugs including anemia treatment Reblozyl, psoriasis drug Sotyktu, and multiple sclerosis drug Zeposia takes longer than expected.
Lire la suite »
Bristol-Myers Squibb earnings top estimatesCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Lire la suite »
Bristol Myers Squibb earnings top estimates even as top-selling drug fights generic competitionBristol Myers Squibb’s revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Revlimid.
Lire la suite »
Turning Michael Myers Into a Supernatural Cult Monster Made Him Less ScaryHalloween: The Curse of Michael Myers introduces the Cult of Thorn and tries to give the iconic killer an unneeded backstory.
Lire la suite »
De La Ghetto, Bryant Myers, Luar La L & YOVNGCHIMI Debut on Hot 100All 21 songs from Bad Bunny’s new LP chart on the Hot 100.
Lire la suite »
Longtime fisherman reflects on his career in Bristol BayDan Barr is eighty-one and a half years old. He fished Bristol Bay for just about half his life.
Lire la suite »